Table 2.
Summary of pain response rates in included studies
| No | Study | Short-term | Long-term | Scale | ||
|---|---|---|---|---|---|---|
| ORR | CRR | ORR | CRR | |||
| 1 | Van den Ende et al. (2019) [8] | – | – | 21/51 (41.2%) | – | OMERACT-OARSI responder |
| 2 | Mahler et al. (2019) [9] | 12/27 (44.4%) | – | – | – | OMERACT-OARSI responder |
| 3 | Minten et al. (2018) [10] | 8/28 (28.6%) | – | – | – | OMERACT-OARSI responder |
| 4 | Ott et al. (2014) [11] | – | – | 285/300 (95%) | 147/300 (49%) | CPS, VAS |
| 5 | Ott et al. (2013) [12] | 187/212 (88.2%) | 42/212 (19.8%) | – | – | CPS, VAS |
| 6 | Hautmann et al. (2020) [47] | 178/271 (65.7%) | 81/256 (31.6%) | 137/216 (63.4%) | 73/216 (33.8%) | NRS |
| 7 | Hautmann et al. (2020) [14] | 36/48 (75%) | 9/48 (18.8%) | 35/46 (76.1%) | 9/46 (19.6%) | NRS |
| 8 | Hautmann et al. (2019) [13] | – | 65/125 (52%) | – | 73/113 (64.6%) | NRS |
| 9 | AYNACI et al. (2021) [16] | 48/67 (71.6%) | 28/67 (41.8%) | – | – | VPS |
| 10 | Rogers et al. (2020) [17] | – | – | – | 110/151 (72.8%) | VAS |
| 11 | Alvarez et al. (2019) [18] | 90/184 (48.9%) | 22/184 (12%) | 57/89 (64%) | 7/89 (7.9%) | VPS |
| 12 | Badakhsi et al. (2014) [19] | 115/171 (67.3%) | – | – | – | Patient’s reported subjective response |
| 13 | Weissmann et al. (2021) [20] | 96/196 (49%) | 71/196 (36.2%) | – | – | Patient’s reported subjective response |
| 14 | Hermann et al. (2021) [21] | 21/25 (84%) | 1/25 (4%) | 12/16 (75%) | 3/16 (18.8%) | VPS |
| 15 | Niewald et al. (2022) [22] | 130/220 (59.1%) | 90/220 (40.9%) | – | – | VAS |
| 16 | Alvarez et al. (2022) [23] | – | – | 63/100 (63%) | 13/100 (13%) | VPS |
| 17 | Rühle et al. (2021) [24] | 711/1185 (60%) | 18/1185 (1.5%) | – | – | VPS |
| 18 | Rudat et al. (2021) [25] | 372/582 (63.9%) | 149/318 (46.9%) | 216/318 (67.9%) | 116/236 (49.2%) | VAS |
| 19 | Donaubauer et al. (2020) [26] | 173/483 (35.8%) | – | – | – | Patient’s reported subjective response |
| 20 | Juniku et al. (2019) [27] | 119/339 (35.1%) | – | 373/598 (62.4%) | – | VAS |
| 21 | Kaltenborn et al. (2017) [28] | 53/74 (71.6%) | 17/52 (32.7%) | 34/47 (72.3%) | 24/47 (51.1%) | Patient’s reported subjective response |
| 22 | Kaltenborn et al. (2016) [29] | 71/101 (70.3%) | 9/65 (13.8%) | 19/27 (70.4%) | 7/27 (25.9%) | Patient’s reported subjective response |
| 23 | Leszek et al. (2015) [30] | 23/28 (82.1%) | 10/28 (35.7%) | 21/24 (87.5%) | 11/24 (45.8%) | Patient questionnaires |
| 24 | Hermann et al. (2013) [31] | – | – | 208/252 (82.5%) | 107/252 (42.5%) | Patient’s reported subjective response |
| 25 | Hajtmanova et al. (2010) [32] | 180/323 (55.7%) | – | – | – | NA |
| 26 | Adamietz et al. (2010) [33] | – | – | 94/115 (81.7%) | – | Orthopedic Constant Score |
| 27 | Keilholz et al. (1998) [34] | 58/96 (60.4%) | 35/96 (36.5%) | – | – | VPS |
| 28 | Seegenschmiedt et al. (1997) [35] | – | – | 69/93 (74.2%) | 50/93 (53.8%) | Morrey score |
| 29 | Heyd et al. (1997) [36] | 31/45 (68.9%) | 7/45 (15.6%) | – | – | Patient’s reported subjective response |
| 30 | Schafer et al. (1996) [37] | 42/90 (46.7%) | – | 68/90 (75.6%) | – | VPS |
| 31 | Keilholz et al. (1995) [38] | – | – | 72/89 (80.9%) | 44/89 (49.4%) | Patient’s objective, subjective symptoms |
| 32 | Sautter-Bihl et al. (1993) [39] | 58/77 (75.3%) | 29/77 (37.7%) | – | – | Patient’s reported subjective response |
| 33 | Hess et al. (1988) [40] | 126/164 (76.8%) | – | – | – | Patient’s reported subjective response |
ORR overall response rate, CRR complete response rate, NRS numeral rating scale, VPS von Pannewitz score, VAS visual analog scale, CPS comprehensive pain score, OMERACT-OARSI Outcome Measures in Rheumatology-Osteoarthritis Research Society International